The results suggest that dipeptidyl peptidase-4 (DDP-4) inhibitors, which are widely prescribed in Germany, are not a cost-effective option despite lower drug pricing compared with empagliflozin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback